Calcification is the principal cause of the clinical failure of bioprosthetic heart valves fabricated from glutaraldehyde pretreated porcine aortic valves or bovine pericardium. The present study investigated controlled-release implants for prevention of the calcification of glutaraldehyde pretreated bovine pericardium in a rat subdermal model. Either A13+ and Fe3+ (inhibitors of the growth and dissolution rate of hydroxyapatite crystals), levamisole (alkaline phosphatase inhibitor) or protamine sulphate (charge modifier) were individually incorporated into various polymeric carriers (either silicone rubber, polyurethane or silicone rubber-polyurethane copolymer). Polymeric implants were evaluated for in vitro release kinetics, which revealed that sustained drug release was obtained from 21 d to more than 90 d from various drug matrices. In viva efficacy was studied by co-implanting the polymeric delivery systems with glutaraldehyde pretreated bovine pericardium for 21 d using a subdermal rat model; glutaraldehyde pretreated bovine pericardium calcium levels were quantitated by atomic absorption spectroscopy in the explanted tissues. Fe'+ and A13+ polymeric implants were the most effective for inhibiting deposition of calcium mineral. AI'+ demonstrated 82% inhibition of calcification compared to controls and Fe3+ resulted in 80% inhibition of calcification. Specific histologic staining methods showed that Fe3+ and A13+ were localized within the devitalized cells of the explanted glutaraldehyde pretreated bovine pericardium. No adverse effects on somatic growth or recipient bone morphology were noted following controlled-release drug administration. Controlled release of protamine sulphate or levamisole did not significantly inhibit glutaraldehyde pretreated bovine pericardium calcification. It is concluded that regional controlled release of Fe3+ or A13+ inhibits glutaraldehyde pretreated bovine pericardium calcification in the rat subdermal model without adverse effects.
mice4-6. Retrieved subdermal bioprosthetic implants yield calcification pathology comparable to that seen in clinical and experimental circulatory explants3.
Circulatory and subdermal investigations of strategies for preventing bioprosthetic calcification have revealed that a disadvantage for the systemic use of anticalcification agents such as diphosphonates is unavoidable side effects on bone and overall growth. However, controlled-release polymer matrices containing ethanehydroxydiphosphanate (EHDP), co-implanted with GPBP, significantly reduce the extent of calcification in both subdermal and circulatory animal models without adverse effects7-'. Site-specific therapy with controlled-release matrices offers the therapeutic advantages of optimally low regional drug levels with minimal systemic side effects.
Other promising anticalcification agents previously demonstrated to be effective as tissue pretreatments have not been studied for their efficacy via controlled release. For example, A13+ pretreatment of GPBP prevents mineralization without generalized side effects" in rat subdermal implant studies for 21 and 60 d, and short-term inhibition was also observed with Fe3+ pretreatment of the GPBP". The mechanism of action of these metallic ions may be due to their propensity to inhibit the growth of hydroxyapatite crystals" and partly due to their inhibitory effect on alkaline phosphatase' 3. Inhibitors of alkaline phosphatase, an important enzyme in physiologic mineralization, may also be of interest, since this enzyme has been shown to be present in porcine and GPBP bioprosthetic tissues both before and following the glutaraldehyde pretreatment14. Levamisole is a well known uncompetitive alkaline phosphatase inhibitor which has been shown to inhibit cartilage calcification in Vitr~'~.
Furthermore, covalent binding of protamine sulphate (PS) to GPBP inhibited calcification in the rat subdermal model and the mechanism of action is hypothesized to be due to charge modification'". Whether non-bound PS is similarly effective in inhibiting calcification is unknown.
The objectives of the present studies were to formulate and PS as anticalcification agents. Silicone rubber, polyurethane and silicone rubber-polyurethane copolymer were each studied as matrix substrates. ln vitro drug release studies under perfect sink conditions at pH 7.4 and 37°C were followed by in viva efficacy investigations using a rat subdermal model of GPBP mineralization. For solvent casting, the anticalcification agent and the polymer were separately dissolved in dimethyl acetamide. The solutions were thoroughly mixed together and the films cast were dried under vacuum at 50°C overnight. The dried films were 0.54 f 0.03 mm thick. The silicone-rubber formulation containing PS was prepared by levigating the prepolymer Silastic Q-7 4840 thoroughly with the drug, followed by compression moulding at 703 070 kg/m2 at 250°C for l-2 h using a hydraulic press to form films of 0.87 f 0.04 mm thickness. Levamisole was incorporated in Silastic X-7 3029 by melt casting at 70°C. The molten mixture was poured into a stainless steel mould and allowed to come to ambient temperature, forming films which were 0.87 ? 0.04 mm thick.
MATERIALS AND METHODS

Reagent
In vitro release
In vitro release was carried out incubating slab materials (1 X 1 cm) at 37°C under perfect sink conditions in either 0.05 M KzHPO, buffer pH 7.4 for levamisole and PS polymeric matrices of 0.05 M HEPES buffer pH 7.4 was used for A13+ and Fe3+ matrices. Samples (1 ml) were periodically withdrawn from the vials for levamisole and PS release studies. Levamisole release was estimated by spectrophotometric detection at 2 13 nm using a Perkin Elmer Lambda 3B spectrophotometer (Norwalk, CT, USA); the PS content was determined by using the Lowry protein assay17. For either A13+ or Fe3+, at each time interval a small piece of each polymeric matrix was removed, dried under vacuum and weighed accurately. The Fe3+ or A13+ content was then determined on each sample by neutron activation analysis18.
In vivo studies
Male rats (CD strain, Charles River, Burlington, MA, USA) 2 1 d old were anaesthetized with an intraperitoneal injection of ketamine and Rompun@. Subcutaneous pouches were created over the anterior abdominal wall, 1 X 1 cm GPBP pieces were implanted in these pouches, either as isolated control of coimplants with polymeric matrices (1 X 1 cm), with or without agents attached with surgical staples. After 2 1 d rats were killed with COz asphyxiation and the GPBPs explanted, lyophilized and hydrolysed in 6 N HCI, using established procedures'g. Calcium levels were determined on aliquots of the hydrolysates by atomic absorption spectroscopylg.
Morphologic assessment
Representative samples of each explanted group were fixed using 2.5% glutaraldehyde and 2.0% paraformaldehyde in cacodylate buffer (pH 7.0) Karnovsky's fixative". Fixed specimens were dehydrated in graded ethanol and embedded in glycolmethylethacrylate. Sections 3 ,u thick were stained 
RESULTS
In vitro release
Release kinetic studies showed that all formulations exhibited an initial burst phase of release, followed by an exponentially decreasing release rate. The results of the in vitro release studies of the polymeric matrices are depicted in (Figure 7) , the predicted dosage per implant was expected to be completely delivered midway through the 2 1 d implant period. Furthermore, the two levamisole preparations provided estimated dosages which differed twenty fold.
In vivo studies
Results of in vivo evaluation of different polymeric implants are presented in Tab/e 2. There was significant inhibition of calcification due to either Fe3+ or A13+ (P < O.OOl), when incorporated in the Silastic 6605-41 matrices. When compared with the control values, > 80% calcification inhibition occurred, due to either 6605-41 matrix system of Fe3+ orA13+. In addition, it was also observed that when A13+ but not Fe3+ was incorporated into Biomer matrices, there was also significant calcification inhibition, although less than observed with the 6605-41 matrices. The Ca levels were 60 and 38% of control for explant for the animals receiving Fe3+ and A13+, respectively, in Biomer matrices. Ca2+ levels in the GPBP, implanted in close proximity to either the levamisole or PS matrices, were not statistically different from the control explanted GPBP. Further, none of the animals experienced any adverse effects on somatic growth of bone development due to the administration of the controlled-release drug administration. 
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